Hanley David C., an insider at Nuvation Bio Inc (NUVB), sold 24,000 shares of the company's stock on November 18, 2025, at a price of $7.14 per share, totaling $171,000. Following this transaction, Hanley retains 24,000 shares of Nuvation Bio.
Nuvation Bio, a biopharmaceutical company based in San Francisco, focuses on developing innovative therapeutic candidates to address unmet needs in oncology. The firm is known for its pipeline, which includes taletrectinib, a selective ROS1 inhibitor for non-small cell lung cancer, and safusidenib, an inhibitor targeting mutant isocitrate dehydrogenase 1. As of November 20, 2025, Nuvation Bio boasts a market capitalization of $2.5 billion, with a trailing twelve-month earnings per share of -0.64.
Insider transactions like this one are reported to the SEC, providing transparency about executive actions. While the sale may raise questions, it is essential to consider that insiders sell shares for various reasons, including personal financial needs or tax planning. Investors are encouraged to analyze insider activity over time and across multiple individuals, rather than focusing solely on isolated transactions.
Looking ahead, Nuvation Bio is set to announce its next earnings results on August 5, 2026, with an estimated EPS of -0.17 and revenue projections of $37.6 million.